> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FTC Settlement Over AndroGel Generics
- URL: https://www.fdaweb.com/ftc-settlement-over-androgel-generics/
- Published: 2019-03-01T12:00:00.000Z
- Updated: 2026-09-15T01:09:14.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5143503

The FTC has reached a [settlement in ](https://www.ftc.gov/system/files/documents/cases/watson%5Ffinal%5Fmotion%5Ffor%5Fpermanent%5Finjunction.pdf?ref=fdaweb.com)[*FTC v. Actavis*](https://www.ftc.gov/system/files/documents/cases/watson%5Ffinal%5Fmotion%5Ffor%5Fpermanent%5Finjunction.pdf?ref=fdaweb.com)*,* a 2009 case alleging that Solvay and three generic drug companies illegally agreed to restrict generic competition to Solvay’s branded testosterone-replacement drug AndroGel for nine years. The settlement covers those products that Solvay may have been marketing or developing before its purchase in 2010 by Abbott, which was later spun off into AbbVie,

Under the settlement, AbbVie is prohibited from entering into certain patent infringement settlement agreements that restrict generic entry for certain drugs and contain common reverse payments, such as: (**1**) a side deal, in which the generic company receives compensation in the form of a business transaction entered at the same time as the patent litigation settlement; or (**2**) a “no-authorized generic commitment,” where a brand company agrees not to compete with an authorized generic version for a period of time.